By comparing the efficacy of phytopharmaceuticals, we concluded that the presence of specific dominant plant metabolites may favorably influence the prognosis of mammary carcinogenesis. However, further preclinical and clinical research is necessary to confirm these findings, including assessing the potential of these agents as adjuvant therapy alongside standard oncological treatment.
Kapinová et al. (Wed,) studied this question.